OptiNose AS

99 articles with OptiNose AS

• Optinose Announces Reporting Date for Second Quarter 2020 Financial Results

  7/30/2020

  Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced the Company will report financial results for the second quarter 2020 and corporate updates, before market open on Tuesday, August 4, 2020.

• Optinose names Catherine E. Owen as Director

  7/29/2020

  Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Board of Directors has named Catherine E. Owen as a new director. Catherine currently serves as Senior Vice President, Major Markets at Bristol-Myers Squibb, overseeing commercial operations for the business in 18 countries including Japan, Germany, France, and others across Europe.  She jo

• Optinose Announces XHANCE Co-Promotion Agreement with Kaléo

  7/8/2020

  Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the signing of an agreement with kaléo, a pharmaceutical company dedicated to building innovative solutions for serious and life-threatening medical conditions, to co-promote XHANCE® (fluticasone propionate) exhalation nasal spray 93 mcg, for the treatment of nasal polyps in patients 18 years or older in the United States. 

• Optinose Announces Anti-COVID-19 Product Candidate

  6/30/2020

  Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced initiation of development of a new product candidate, OPN-019.

• Optinose to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

  6/22/2020

  Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 9:00 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose websit

• Optinose to Host its Annual Meeting of Stockholders in Virtual Format

  5/27/2020

  OptiNose, Inc. announced that due to the public health and safety concerns related to the novel coronavirus pandemic and recommendations and orders from federal and state governmental authorities, its Annual Meeting of Stockholders will now be held by means of a virtual format only.

• Optinose to Present at the 2020 Jefferies Virtual Healthcare Conference

  5/26/2020

  Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the 2020 Jefferies Virtual Healthcare Conference on June 2, 2020, at 1:30 p.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay

• Optinose to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

  5/14/2020

  Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced that Chief Executive Officer Peter Miller will present a company overview and business update at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on May 19, 2020, at 10:20 a.m. ET.

• Optinose Reports First Quarter 2020 Financial Results and Operational Updates

  5/7/2020

  Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter ended March 31, 2020, and provided operational updates.

• Optinose Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Operational Highlights

  3/5/2020

  Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2019, and provided recent operational highlights.

• 

  BioSpace Movers & Shakers, Feb. 21

  2/21/2020

  Biopharma and life sciences companies strengthen their leadership teams and board with this week's Movers & Shakers.

• Optinose Appoints Victor Clavelli as Chief Commercial Officer

  2/19/2020

  YARDLEY, Pa., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Victor M. Clavelli as Chief Commercial Officer. Mr. Clavelli joins Optinose from Pfizer where, in the course of an accomplished 20-year career, he held leadership roles including marketing, sales, and regulatory affairs. Most recently, he served as the North American President f

• Optinose Announces Pricing of Public Offering of Common Stock

  11/21/2019

  The offering is expected to close on or about November 25, 2019, subject to the satisfaction of customary closing conditions.

• Optinose Announces Proposed Public Offering of Common Stock

  11/20/2019

  Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it and certain selling stockholders intend to offer and sell shares of its common stock in an underwritten public offering.

• Optinose Reports Third Quarter 2019 Financial Results and Recent Operational Highlights

  11/12/2019

  Optinose reported financial results for the quarter ended September 30, 2019, and provided recent operational highlights.

• Optinose to Report Third Quarter 2019 Financial Results and Corporate Updates on November 12, 2019Conference Call and Webcast Scheduled for Tuesday, November 12 at 4:30 p.m. Eastern Time

  11/1/2019

  Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the third quarter 2019, after market close on Tuesday, November 12, 2019.

• Currax™ Pharmaceuticals LLC Announces First Acquisition: Acquires North American Rights to ONZETRA® Xsail®

  9/26/2019

  Currax Pharmaceuticals LLC announced a deal whereby Currax obtained patent rights to ONZETRA® Xsail® in North America from OptiNose AS, a subsidiary of OptiNose, Inc..

• Avanir Pharmaceuticals Announces Termination of License Agreement with Optinose for ONZETRA® Xsail®

  12/11/2018

  Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists.

• Optinose to Highlight Data at Two Upcoming October 2018 Scientific Meetings

  10/3/2018

  Optinose today announced that data concerning its product XHANCE® will be presented at the American Rhinologic Society (ARS) 64th Annual Meeting in Atlanta, Georgia, October 5-6, 2018, and the American Academy Of Otolaryngology-Head and Neck Surgery Annual Meeting in Atlanta, Georgia, October 7-10, 2018.

• 

  Optinose Gets $100M Debt Financing From Athyrium Capital Management

  1/2/2018

  At closing of the agreement, $75 million in aggregate principal amount of the Senior Secured Notes were issued.